Melatonin–selenium nanoformulation: a promising therapeutic strategy against Ehrlich ascites carcinoma
Hanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour · 2026
Read Melatonin–selenium nanoformulation: a promising therapeutic strategy against Ehrlich ascites carcinoma by Hanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13212612.txt.
Description
Hanaa M. Morad, A. F. Abdel-Aziz, and Mai M. Madkour report in 2026 on tiny particles combining melatonin with selenium as a possible cancer treatment. Their test system was a fast-growing mouse tumour model widely used for early screening of anticancer compounds.
In treated animals, the combined particles slowed tumour growth and strengthened antioxidant defences better than either ingredient alone. A key inflammatory signal fell, and tumour cells showed more programmed death, with a growth marker reduced and cell division stalled at an early phase. The results are early and animal-based, yet they support testing this multi-target pairing further before any claims about human use.
Catalog record
| CREATOR | Hanaa M. Morad, A. F. Abdel-Aziz, Mai M. Madkour |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |